Cell-free Protein Expression Market

Market Overview:

The global cell-free protein expression market size reached US$ 246.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 323.8 Million by 2028, exhibiting a growth rate (CAGR) of 7.61% during 2023-2028.

Cell-free protein expression (CFPE) refers to the production of desired recombinant proteins in solution using biomolecular translation machinery extracted from cells. It can be carried out using different cell lysates, such as E. coli, rabbit reticulocytes, wheat germ, insect cells, and mammalian cell-free protein expression systems. They are widely used in enzyme engineering, protein labeling, protein purification, protein-protein interaction, and high throughput production of mutants. CFPE is also used for analyzing components needed for protein stability, degradation, and folding. As compared to cell-based protein expression, cell-free protein expression is time efficient and convenient, allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity.

Cell-free Protein Expression Market Trends:

The rapid advancement in biological sciences is one of the key factors driving the market growth. Cell-free protein expression is extensively used in the expansion of genetic code, assembly of viruses, and the synthesis of recombinant proteins for various biomolecular processes. Furthermore, the increasing technique utilization in the pharmaceutical industry for developing protein-based therapeutics, such as antibodies, antimicrobials, and cytokines, for treating cancer and infectious diseases is acting as another growth-inducing factor. Additionally, the integration of machine learning (ML) algorithms to improve protein production yield by optimizing the system for efficient prototyping and high-throughput experimentation is providing an impetus to market growth. Moreover, the introduction of novel processes to produce complex prokaryotic and eukaryotic proteins using a continuous-exchange cell-free (CECF) protein synthesis system is creating a positive outlook for the market. Other factors, including the widespread adoption of cell-free methods for biomanufacturing and prototyping, extensive research and development (R&D) activities in proteomics and genomics, and the rising adoption in the healthcare industry for diagnostic applications, such as pathogen sensing, inflammatory response, and personalized medicine, are supporting drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cell-free protein expression market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, method, application and end user.

Breakup by Product:

• Expression Systems
  • E. coli Cell-free Protein Expression System
  • Wheat Germ Cell-free Protein Expression System
  • Rabbit Reticulocytes Cell-free Protein Expression System
  • Insect Cells Cell-free Protein Expression System
  • Human Cell-free Protein Expression System
  • Others
• Reagents
   

Breakup by Method:

• Transcription and Translation Systems 
• Translation Systems
   

Breakup by Application:

• Enzyme Engineering
• High Throughput Production
• Protein Labeling
• Protein-Protein Interaction
• Protein Purification
   

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bioneer Corporation, biotechrabbit GmbH, Cambridge Isotope Laboratories Inc. (Otsuka Pharmaceutical Co. Ltd.), CellFree Sciences Co. Ltd., Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Merck KGaA, New England Biolabs, Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.

Report Coverage: